NCT00811395 - Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Multiple Sclerosis

Interventions

DRUG

Teriflunomide

"Film-coated tablet~Oral administration"

DRUG

Placebo (for teriflunomide)

"Film-coated tablet~Oral administration"

DRUG

Interferon-β [IFN-β]

Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection

DRUG

Glatiramer Acetate [GA]

Solution in prefilled syringe for subcutaneous injection

Trial Locations (7)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford